Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...

Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship

Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship

Pharmacodynamics explores the relationship between drug concentration and its effect. In a quantal response drug, the duration of action better correlates with drug concentration, while for graded effect drugs, the intensity of response is more relevant. This intensity depends on the dose, drug removal rate, and the region of the concentration–response curve.The concentration–response curve can be divided into three regions. Region 3 (80–100% maximum response) demonstrates that even as drug...

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...

Pharmacodynamic Models: Linear Concentration–Effect Model

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: "Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance From Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration".

Pharmaceutical research·2025

Same author

Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.

European journal of clinical pharmacology·2017

Same author

Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.

Clinical and translational science·2017

Same author

Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women.

CPT: pharmacometrics & systems pharmacology·2016

Same author

Levofloxacin-Induced QTc Prolongation Depends on the Time of Drug Administration.

CPT: pharmacometrics & systems pharmacology·2016

Same author

Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.

British journal of pharmacology·2016

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally

J W Mandema¹, M Danhof

¹Center for Bio-Pharmaceutical Sciences, Division of Pharmacology, University of Leiden, The Netherlands.

Clinical Pharmacokinetics

|September 1, 1992

Summary

Electroencephalogram (EEG) parameters offer objective measures for central nervous system (CNS) drug effects. Quantitative EEG analysis aids pharmacokinetic-pharmacodynamic modeling, revealing drug potency and efficacy for benzodiazepines and anesthetics.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays

Published on: February 9, 2022

Related Experiment Videos

Last Updated: Jul 18, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays

Published on: February 9, 2022

Area of Science:

Neuroscience
Pharmacology
Biomedical Engineering

Background:

Electroencephalogram (EEG) effect parameters are valuable for pharmacokinetic-pharmacodynamic (PK-PD) modeling of central nervous system (CNS) drugs.
Quantitative EEG analysis provides continuous, objective, sensitive, and reproducible measures suitable for pharmacodynamic characterization.
EEG parameters can help elucidate concentration-effect relationships for drugs like benzodiazepines and intravenous anesthetics.

Purpose of the Study:

To evaluate the utility of EEG effect parameters in PK-PD modeling of CNS drugs.
To explore the application of EEG in characterizing the potency and intrinsic efficacy of benzodiazepines and intravenous anesthetics.
To investigate the influence of various factors on drug concentration-effect relationships using EEG.

Main Methods:

Quantitative analysis of EEG signals to derive effect parameters.
Development of concentration-effect relationships using EEG data.
Correlation of EEG-derived pharmacodynamic parameters with other in vitro and in vivo measurements.
Comparison of EEG measures with clinical endpoints for anesthetic depth.

Main Results:

Changes in beta frequency band amplitudes of EEG signals correlate with the pharmacological intensity of benzodiazepines, reflecting affinity and efficacy at GABA receptors.
EEG measurements show close correlations with clinical measures of anesthetic depth for intravenous anesthetics.
EEG parameters demonstrate potential for monitoring drug effects and understanding influences of factors like age and drug interactions.

Conclusions:

EEG effect parameters are well-suited for PK-PD modeling of CNS drugs, offering quantitative insights into drug action.
EEG analysis, particularly beta band activity, serves as a relevant measure for benzodiazepine effects and anesthetic depth.
Further research is needed to fully elucidate EEG correlates of specific drug actions and optimize their use in clinical settings.